Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen in Diabetic Foot Syndrome
NCT07391319Phase 3Recruiting
- Sponsor
- NextGen
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 3 trial of neovasculgen in diabetic foot syndrome, sponsored by NextGen. Started Feb 2025; status: recruiting.
02
Drugs
neovasculgen
03
Conditions
diabetic foot syndrome
Beyond the preview
Go deeper on NCT07391319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391319.